meningococcal disease

[키워드] 24 hour 24 hours acute hypoxic respiratory failure acute lung injury acute respiratory distress syndrome addition Adult patient alveolar pressure antibiotic Antibiotics anticipated arterial pressure Bacterial blinded Blinding Caregivers ceftriaxone characterized ciprofloxacin clinical Clinical course Combination comparator comparator Patients complement complement C5 inhibition complement pathways complement system component components control arm control group COVID-19 COVID-19 patient CT scan Cytokine release syndrome defined discharge discharged patient discharged patients disease dissemination Effect Efficacy and safety element eligibility criteria EudraCT exclusion criteria experimental arm Fungal infection history hospital discharge hospitalized patient hospitalized patients hospitals hypoxia hypoxic respiratory failure ICU ICUs Identifier improving oxygenation inclusion criteria individual Infection inhibiting inhibitor Interactive Web Response System invasive IV infusion LDH lead lung Lung injury lymphopenia Mechanical mechanical ventilation median meningococcal disease meningococcal infections number objective Open-label open-label trial outcome oxygen oxygen) Oxygenation pandemic PaO parameters Partial participant Participants Patient Phase 2 predict predisposition primary endpoint promote prophylactic antibiotics protocol randomisation randomised randomised controlled trial randomization Randomized receive recent recruited recruitment REDCap Registered repair mechanism Respiratory failure response Sample size SARS-COV-2 infection Serum ferritin SIGN SpO2 Standard of care status Study protocol subcutaneously supplemental oxygen supplementary material System systemic cytokine release syndrome Trial Trial registration Ventilation Version Web website zilucoplan
[DOI] 10.1186/s13063-020-04884-0 PMC 바로가기 [Article Type] Letter